146 related articles for article (PubMed ID: 7980232)
1. Second malignant neoplasms in patients with Hodgkin's disease.
Robinson BA; Colls BM; Fitzharris BM; Atkinson CH
Aust N Z J Med; 1994 Aug; 24(4):368-73. PubMed ID: 7980232
[TBL] [Abstract][Full Text] [Related]
2. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
3. Second malignant tumours in childhood Hodgkin's disease.
Jenkin D; Greenberg M; Fitzgerald A
Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
[TBL] [Abstract][Full Text] [Related]
4. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
Swerdlow AJ; Barber JA; Horwich A; Cunningham D; Milan S; Omar RZ
Br J Cancer; 1997; 75(1):116-23. PubMed ID: 9000608
[TBL] [Abstract][Full Text] [Related]
5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
6. Incidence of second cancers in patients treated for Hodgkin's disease.
Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
[TBL] [Abstract][Full Text] [Related]
7. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
8. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
9. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
[TBL] [Abstract][Full Text] [Related]
10. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
12. Second cancer among long-term survivors from Hodgkin's disease.
Nyandoto P; Muhonen T; Joensuu H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
14. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Longo DL; DeVita VT
Important Adv Oncol; 1992; ():155-65. PubMed ID: 1582671
[No Abstract] [Full Text] [Related]
15. Hodgkin's disease: summary of twenty years' experience.
Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
[TBL] [Abstract][Full Text] [Related]
16. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
[TBL] [Abstract][Full Text] [Related]
17. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
19. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
[TBL] [Abstract][Full Text] [Related]
20. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
